AstraZeneca finds early-stage success with MET inhibitor in lung cancer - BioPharma Dive

AstraZeneca finds early-stage success with MET inhibitor in lung cancer  BioPharma Dive

AstraZeneca and Chi-Med's investigational MET inhibitor gave lung cancer patients additional benefit when used in combination with the British pharma's EFGR ...